Developing new methods for the treatment of malignant brain tumours: Local delivery of anti-neoplastic agents using biodegradable polymers

FORUM - Trends in Experimental and Clinical Medicine

Volumn 10, Issue 2, 2000, Pages 152-163

  Olivi, A ^a   DiMeco, F ^a   Bohan, E ^a   Brem, H ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biodegradable polymers; Drug delivery; Microspheres; Tumour

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CARBOPLATIN; CARMUSTINE; DIMER; DOXORUBICIN; FATTY ACID; FLUOROURACIL; INTERLEUKIN 2; MINOCYCLINE; PACLITAXEL; PLACEBO; PLATINUM DERIVATIVE; POLY[1,3 BIS(CARBOXYPHENOXY)PROPANE CO SEBACIC ACID]; POLYMER; SEBACIC ACID; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; BIODEGRADATION; BLOOD BRAIN BARRIER; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM; CHEMICAL STRUCTURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TOXICITY; GLIOMA; HUMAN; IMPLANTATION; MALIGNANT NEOPLASTIC DISEASE; METHODOLOGY; MULTICENTER STUDY; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RAT; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; BIODEGRADATION, ENVIRONMENTAL; BRAIN NEOPLASMS; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; DRUG EVALUATION; GLIOMA; HUMANS; MICROSPHERES; POLYMERS;

EID: 0033941603     PISSN: 11218142     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Cancer Statistics
2. Brain Tumors - Part I.
3. Assumptions in the radiotherapy of glioblastoma
4. New methods in drug delivery
5. Polymers for the sustained release of proteins and other macromolecules
6. Drug delivery to the central nervous system: A review
7. Polyanhydrides as drug delivery systems
8. Controlled delivery of water soluble and hydrolytically unstable anti-cancer drugs for polymeric implants
9. Medical application of controlled release
10. Bioerodable polyanhydrides as drug-carrier matrices: II. Biocompatibility and chemical reactivity
11. Biocompatibility of a biodegradable, controlled-release polymer in the rabbit brain
12. Brain biocompatibility of a biodegradable, controlled-release polymer in rats
13. Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain
14. The antitumor agent 1,3-bis(2-chloroethyl)-1-nitrosourea
15. The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers
16. Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycy- clophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain
17. Interstitial chemotherapy of the 9L gliosarcoma: Controlled release polymers for drug delivery in the brain
18. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas
19. The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: Phase I trial
20. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas The Polymer-brain tumor treatment group [see comments]
21. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: A randomized double-blind study
22. Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors
23. Results of a phase I study of interstitial BCNU administered via wafers to patients with recurrent malignant glioma
24. Local delivery of chemotherapy and concurrent external beam radiotherapy prolongs survival in metastatic brain tumor models
25. Local delivery of chemotherapy prolongs survival in experimental brain metastases from breast carcinoma
26. Cytotoxicity of taxol in vitro against human and rat malignant brain tumors
27. Distribution and metabolism of 3H-Taxol in the rat
28. Preirradiation paclitaxel in glioblastome multiforme: efficacy, pharmacology, and drug interactions
29. Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma
30. Local delivery of the topoi-somerase I inhibitor camptothecin sodium prolongs survival in the rat intracranial 9L gliosarcoma model
31. Cytotoxicity of camptothecin analogs in vitro against glioma cells
32. Carboplatin in childhood brain tumors. A children's cancer study group phase II trial
33. Comparison of the cytotoxic activities of cisplatin and carboplatin a against glioma cell lines at pharmacologically relevant drug exposures
34. Treatment of recurrent malignant supratentorial gliomas with carboplatin (CBDCA)
35. Prolonged response to carboplatin in an infant with brain stem glioma
36. Carboplatin-induced regression of an optic pathway tumor in a child with neurofibromatosis
37. Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain tumor barrier in the treatment of intracranial neoplasms
38. Results of a Southwest Oncology Group Phase II Trial of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide in advanced ovarian cancer
39. Direct delivery of platinum-based antineoplastics to the central nervous system: A toxicity and ultrastructural study
40. Interstitial delivery of carboplatin via biodegradable polymers is effective against experimental glioma in the rat
41. Potentiation of anticancer effects of microencapsulated carboplatin by hydroxypropyl α-cyclodextrin
42. Effectiveness of controlled release of a cyclophosphamide derivative with polymers against rat gliomas
43. Adriamycin impregnated polymers for local treatment of intracranial neoplasms
44. Effect of stereotactic implantation of biodegradable 5-fluorouracil- loaded microspheres in healthy and C6 glioma-bearing rats
45. The development of new brain tumor therapy utilizing the local and sustained delivery of chemotherapeutic agents from biodegradable polymers [editorial; comment]
46. Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for radiosensitization of glioblastoma: Pilot study
47. A review of the pharmacokinetics and pharmacodynamics of combination carboplatin/paclitaxel
48. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer
49. Paclitaxel/carboplatin plus ifosfamide in non-small cell lung cancer
50. Paclitaxel/carboplatin in the treatment of non-small-cell lung cancer
51. Experience with new chemotherapeutic agents in non-small cell lung cancer
52. Effects of carboplatin in combination with other anticancer agents on human leukemia cell lines
53. A phase I clinical and pharmacologic study of a carboplatin and irinotecan regimen combined with recombinant human granulocyte-colony stimulating factor in the treatment of patients with advanced non small cell lung carcinoma
54. Carboplatin in association with etoposide and either adriamycin or epirubicin for untreated small cell lung cancer: A dose escalation study of carboplatin. UCL Clinical Oncology Group
55. 2 carboplatin (Cb), adriamycin (A) cyclophosphamide (C) (CACb-300) combination in advanced ovarian carcinoma: A feasibility study
56. Phase II study of carboplatin and adriamycin as second line chemotherapy in small cell lung cancer
57. Synergistic cytotoxicity of different alkylating agents for epithelial ovarian cancer
58. Retreatment of recurrent invasive thymoma with platinum, doxorubicin, and cyclophosphamide
59. Growth inhibition of the 9L glioma using polymers to release heparin and cortisone acetate
60. Angiogenesis inhibition by minocycline
61. The role of minocycline in the treatment of intracranial 9L glioma
62. Systemic and local paracrine cytokine therapies using transduced tumor cells are synergistic in treating intracranial tumors
63. Intracranial paracrine interleukin-2 therapy stimulates prolonged anti- tumor immunity which extends outside the central nervous system
64. Paracrine delivery of IL-12 against intracranial 9L gliosarcoma in rats
65. Local interleukin-2 delivery eradicates brain and liver tumors
66. Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF secreting cancer cell vaccines
67. Immune response against large tumors aradicated by treatment with cyclophospamide and IL-12
68. Paracrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors